MOUNTAIN VIEW, Calif., Nov. 6, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI ), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 2013 Credit Suisse Annual Health Care Conference on Wednesday, November 13, 2013, at 11:00 a.m. Mountain Time at the The Phoenician in Scottsdale, AZ.
A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . A replay of the webcast will be available on the Company's website for two weeks following the live presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis; CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.
CCXI-G
Source: ChemoCentryx, Inc.
ChemoCentryx: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 Media: Susan Kinkead Kinkead Communications, Inc. 415-751-3611 Investors: Caitlyn Murphy Burns McClellan 212-213-0006
